Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials
Wenhui Xie, Yanrong Huang, Shiyu Xiao, et al.
Annals of the Rheumatic Diseases (2019) Vol. 78, Iss. 8, pp. 1048-1054
Closed Access | Times Cited: 154

Showing 1-25 of 154 citing articles:

Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis
Pablo A. Olivera, Juan S. Lasa, Stefanos Bonovas, et al.
Gastroenterology (2020) Vol. 158, Iss. 6, pp. 1554-1573.e12
Open Access | Times Cited: 260
<p>JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data</p>
Robert Harrington, Shamma Ahmad Al Nokhatha, Richard Conway
Journal of Inflammation Research (2020) Vol. Volume 13, pp. 519-531
Open Access | Times Cited: 175
Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis
Anne Grete Semb, Eirik Ikdahl, Grunde Wibetoe, et al.
Nature Reviews Rheumatology (2020) Vol. 16, Iss. 7, pp. 361-379
Closed Access | Times Cited: 165
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
Jacopo Angelini, Rossella Talotta, Rossana Roncato, et al.
Biomolecules (2020) Vol. 10, Iss. 7, pp. 1002-1002
Open Access | Times Cited: 150
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
Peter C. Taylor, Tsutomu Takeuchi, Gerd R Burmester, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 3, pp. 335-343
Open Access | Times Cited: 116
The JAK–STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms
Chiara Baldini, Francesca Romana Moriconi, Sara Galimberti, et al.
European Heart Journal (2021) Vol. 42, Iss. 42, pp. 4389-4400
Open Access | Times Cited: 111
Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
Léa Hoisnard, Bénédicte Lebrun‐Vignes, Sébastien Maury, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 100
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Léa Hoisnard, Laura Pina Vegas, Rosemary Dray‐Spira, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 182-188
Closed Access | Times Cited: 90
Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease
Brittany Weber, Jon T. Giles, Katherine P. Liao
Nature Reviews Rheumatology (2023) Vol. 19, Iss. 7, pp. 417-428
Open Access | Times Cited: 79
Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis
Sizheng Steven Zhao, David R. Riley, Gema Hernandez, et al.
Clinical Therapeutics (2025)
Open Access | Times Cited: 3
JAK Inhibitors: Prospects in Connective Tissue Diseases
Hanxiao You, Dong Xu, Jiuliang Zhao, et al.
Clinical Reviews in Allergy & Immunology (2020) Vol. 59, Iss. 3, pp. 334-351
Closed Access | Times Cited: 105
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease
Pablo A. Olivera, Stéphane Zuily, Paulo Gustavo Kotze, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 12, pp. 857-873
Open Access | Times Cited: 105
The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review
Peter C. Taylor, Fabiola Atzeni, Alejandro Balsa, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 3, pp. 509-509
Open Access | Times Cited: 81
Cardiovascular effects of approved drugs for rheumatoid arthritis
Fabiola Atzeni, Javier Rodríguez‐Carrio, Călin D. Popa, et al.
Nature Reviews Rheumatology (2021) Vol. 17, Iss. 5, pp. 270-290
Closed Access | Times Cited: 79
JAK inhibitors: Ten years after
Francesca Romana Spinelli, Françoise Meylan, John J. O’Shea, et al.
European Journal of Immunology (2021) Vol. 51, Iss. 7, pp. 1615-1627
Open Access | Times Cited: 78
Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication
Yutaka Kawahito, Akio Morinobu, Yuko Kaneko, et al.
Modern Rheumatology (2022) Vol. 33, Iss. 1, pp. 21-35
Open Access | Times Cited: 68
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis
Viktor Molander, Hannah Bower, Thomas Frisell, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 189-197
Open Access | Times Cited: 65
Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019
Juliana Setyawan, Nassir Azimi, Vibeke Strand, et al.
Drug Safety (2021) Vol. 44, Iss. 8, pp. 889-897
Open Access | Times Cited: 63
Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study
Rishi Desai, Ajinkya Pawar, Farzin Khosrow‐Khavar, et al.
Lara D. Veeken (2021) Vol. 61, Iss. 1, pp. 121-130
Open Access | Times Cited: 59
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Soo‐Young Na, Chang Hwan Choi, Eun Mi Song, et al.
Intestinal Research (2022) Vol. 21, Iss. 1, pp. 61-87
Open Access | Times Cited: 39
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
Thomas Bieber, Eugen Feist, Alan D. Irvine, et al.
Advances in Therapy (2022) Vol. 39, Iss. 11, pp. 4910-4960
Open Access | Times Cited: 39
Metaflammation in glucolipid metabolic disorders: Pathogenesis and treatment
Pingjie Xiong, Fan Zhang, Fang Liu, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114545-114545
Open Access | Times Cited: 29
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib
Ling Peng, Kui Xiao, Silvia Ottaviani, et al.
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 11, pp. 1505-1511
Open Access | Times Cited: 70
JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications
Manasi Agrawal, Eun Soo Kim, Jean‐Frédéric Colombel
Journal of Crohn s and Colitis (2020) Vol. 14, Iss. Supplement_2, pp. S755-S760
Open Access | Times Cited: 69
The role of interferon-γ in cardiovascular disease: an update
Ailin Elyasi, Iryna Voloshyna, Saba Ahmed, et al.
Inflammation Research (2020) Vol. 69, Iss. 10, pp. 975-988
Closed Access | Times Cited: 61
Page 1 - Next Page

Scroll to top